Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Raw Materials: 2011-2018

Historic Raw Materials for Anika Therapeutics (ANIK) over the last 7 years, with Sep 2018 value amounting to $13.2 million.

  • Anika Therapeutics' Raw Materials rose 68.31% to $13.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $13.2 million, marking a year-over-year increase of 68.31%. This contributed to the annual value of $11.3 million for FY2017, which is 91.98% up from last year.
  • Per Anika Therapeutics' latest filing, its Raw Materials stood at $13.2 million for Q3 2018, which was up 5.24% from $12.6 million recorded in Q2 2018.
  • Over the past 5 years, Anika Therapeutics' Raw Materials peaked at $13.2 million during Q3 2018, and registered a low of $4.9 million during Q3 2015.
  • For the 3-year period, Anika Therapeutics' Raw Materials averaged around $8.3 million, with its median value being $6.8 million (2016).
  • Per our database at Business Quant, Anika Therapeutics' Raw Materials decreased by 28.96% in 2015 and then spiked by 100.13% in 2018.
  • Over the past 5 years, Anika Therapeutics' Raw Materials (Quarterly) stood at $6.2 million in 2014, then declined by 6.20% to $5.8 million in 2015, then rose by 1.80% to $5.9 million in 2016, then soared by 91.98% to $11.3 million in 2017, then skyrocketed by 68.31% to $13.2 million in 2018.
  • Its Raw Materials stands at $13.2 million for Q3 2018, versus $12.6 million for Q2 2018 and $10.1 million for Q1 2018.